triumph 1 trial retatrutide Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial

The numbers from Lilly's Phase 3 retatrutide trial dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user

25.93

★★★★☆4.8 (126)

TRIUMPH-1 trial results: Retatrutide, the triple agonist. Significant weight loss ( 28.3% average loss at 80 weeks). It has potential to transform obesity treatment with results comparable to bariatric surgery

27.69

★★★★★4.9 (98)

⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with obesity or “overweight”

23.05

★★★★★5.0 (157)

Looking forward to when #retatrutide's Phase 3 trial results will become available. There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating obesity and its complications: #type2diabetes #cardiovascular disease

27.97

★★★★★4.7 (84)

Eli Lilly and Company Reports Phase 3 TRIUMPH-1 Trial Shows Up to 30.3% Weight Loss with Retatrutide in Obesity

21.09

★★★★★4.9 (203)

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)

20.29

★★★★★5.0 (176)

As a medical school professor, I have watched obesity pharmacology jump three generations in five years. Eli Lilly just announced TRIUMPH-1 results unlike anything short of bariatric surgery. (1/4)

28.33

★★★★★4.8 (132)